PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Retatrutide>>benefits
Clinical-stage

Retatrutide Benefits: What Phase 2 Actually Reported

Retatrutide is investigational. Its phase 2 results were striking, and everything reported here will be re-tested in phase 3 — the correct frame for an unapproved compound.

Phase 2 weight outcomes

In the dose-ranging phase 2 trial (n=338), the highest dose produced ~17.5% mean weight reduction at 24 weeks, with ~24% reported at 48 weeks — the largest pharmacological weight effects published to that date.

Metabolic endpoints

Phase 2 also reported HbA1c improvements in participants with type 2 diabetes and favorable changes in lipids and blood pressure across the dose range.

What phase 3 is testing

The registrational program (TRIUMPH series in obesity; parallel T2D and MASH programs) is testing whether the phase 2 signal reproduces at scale, and characterizing the safety profile that would support approval.

The honest frame

"Investigational with strong phase 2" is a real category — and it is not "almost approved." Efficacy signals that fail at phase 3 are common enough that this catalog reports, and waits.

Educational content only — not medical advice. This compound is not an approved medicine; no dosing guidance is or will be provided.

References

  1. ClinicalTrials.gov — registered retatrutide studies. [source]
  2. Newman JC, et al. Retatrutide phase 2 results. N Engl J Med 2023 (see trial record for details). [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement